AV 608

Drug Profile

AV 608

Alternative Names: AV-608; CGP-60829; NK-608; NKP 608C; NKP608

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Developer Avera Pharmaceuticals
  • Class Anxiolytics; Piperidines; Quinolines
  • Mechanism of Action Neurokinin 1 antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Overactive bladder; Social phobia

Most Recent Events

  • 19 Jul 2010 Discontinued - Phase-II for Social phobia in USA (PO)
  • 19 Jul 2010 Discontinued - Phase-II for Overactive bladder in United Kingdom (PO)
  • 19 Jul 2010 Discontinued - Phase-II for Overactive bladder in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top